FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051284343> ?p ?o ?g. }

• W2051284343 endingPage "228" @default.
• W2051284343 startingPage "223" @default.
• W2051284343 abstract "Dabigatran, an oral direct thrombin inhibitor, is FDA approved for the prevention of stroke in patients with nonvalvular atrial fibrillation. No agent exists for the reversal of dabigatran-related major bleeding. Prothrombin complex concentrate (PCC) has been studied in reversal but was not shown to affect the surrogate markers of bleeding such as the thrombin time, ecarin clotting time, or activated partial thromboplastin time (aPTT). Recombinant factor VIIa (rFVIIa) may provide benefit in patients with life-threatening or major bleeding; however, it has not been studied in dabigatran-related bleeding. PCC and rFVIIa are agents utilized at our institution for major bleeding in patients receiving anticoagulant therapy. Due to the high cost and thrombogenic risk of both rVIIa and PCC and lack of a clear reversal strategy, we reviewed the management of all reported cases of dabigatran-related bleeding.This was a retrospective chart review of patients admitted to UMass Memorial Medical Center with a bleeding event and also receiving dabigatran therapy.Eleven patients on dabigatran admitted for bleeding were identified. Seven were admitted for an intracranial hemorrhage (ICH) and four for a gastrointestinal hemorrhage (GIH). The baseline characteristics are as follows: mean age was 74.55 years (range, 63-89), and seven were male. Admission mean hemoglobin was 11.88 g/dl (range, 6.1-18), mean international normalized ratio (INR) was 2.2 (range, 1.1-7.1), and mean aPTT was 42.21 s (range, 36-81.4). Interventions received included fresh frozen plasma (n = 6), platelets (n = 3), packed red blood cells (n = 4), rFVIIa (n = 2), intravenous fluids (n = 10), surgical intervention (n = 3), and dialysis (n = 2). No patients received PCC. Four patients survived in the ICH group, and four patients survived in the GIH group.Reversal strategies for dabigatran-related bleeding events at our institution are highly variable. Intracranial hemorrhage in patients on dabigatran was associated with 43 % mortality. Patients with severe dabigatran-related bleeding may benefit from a standardized approach to treatment." @default.
• W2051284343 created "2016-06-24" @default.
• W2051284343 creator A5042919687 @default.
• W2051284343 creator A5045682455 @default.
• W2051284343 creator A5065778617 @default.
• W2051284343 creator A5069915414 @default.
• W2051284343 date "2014-01-03" @default.
• W2051284343 modified "2023-10-17" @default.
• W2051284343 title "Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series" @default.
• W2051284343 cites W1998354077 @default.
• W2051284343 cites W2018609108 @default.
• W2051284343 cites W2048075335 @default.
• W2051284343 cites W2057250169 @default.
• W2051284343 cites W2073308951 @default.
• W2051284343 cites W2113446992 @default.
• W2051284343 cites W2114740459 @default.
• W2051284343 cites W2127448793 @default.
• W2051284343 cites W2136489990 @default.
• W2051284343 cites W2138047112 @default.
• W2051284343 cites W2139493228 @default.
• W2051284343 cites W2153419241 @default.
• W2051284343 cites W2159578495 @default.
• W2051284343 cites W2334285353 @default.
• W2051284343 cites W2481569543 @default.
• W2051284343 doi "https://doi.org/10.1007/s13181-013-0364-1" @default.
• W2051284343 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4057537" @default.
• W2051284343 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24385325" @default.
• W2051284343 hasPublicationYear "2014" @default.
• W2051284343 type Work @default.
• W2051284343 sameAs 2051284343 @default.
• W2051284343 citedByCount "21" @default.
• W2051284343 countsByYear W20512843432014 @default.
• W2051284343 countsByYear W20512843432015 @default.
• W2051284343 countsByYear W20512843432016 @default.
• W2051284343 countsByYear W20512843432017 @default.
• W2051284343 countsByYear W20512843432018 @default.
• W2051284343 countsByYear W20512843432019 @default.
• W2051284343 countsByYear W20512843432020 @default.
• W2051284343 countsByYear W20512843432022 @default.
• W2051284343 crossrefType "journal-article" @default.
• W2051284343 hasAuthorship W2051284343A5042919687 @default.
• W2051284343 hasAuthorship W2051284343A5045682455 @default.
• W2051284343 hasAuthorship W2051284343A5065778617 @default.
• W2051284343 hasAuthorship W2051284343A5069915414 @default.
• W2051284343 hasBestOaLocation W20512843432 @default.
• W2051284343 hasConcept C126322002 @default.
• W2051284343 hasConcept C141071460 @default.
• W2051284343 hasConcept C2776301958 @default.
• W2051284343 hasConcept C2776413415 @default.
• W2051284343 hasConcept C2776710957 @default.
• W2051284343 hasConcept C2777091921 @default.
• W2051284343 hasConcept C2778080469 @default.
• W2051284343 hasConcept C2778261982 @default.
• W2051284343 hasConcept C2778382381 @default.
• W2051284343 hasConcept C2778661090 @default.
• W2051284343 hasConcept C2778810321 @default.
• W2051284343 hasConcept C2778961111 @default.
• W2051284343 hasConcept C2779161974 @default.
• W2051284343 hasConcept C2780434524 @default.
• W2051284343 hasConcept C42219234 @default.
• W2051284343 hasConcept C66112548 @default.
• W2051284343 hasConcept C71924100 @default.
• W2051284343 hasConcept C89560881 @default.
• W2051284343 hasConceptScore W2051284343C126322002 @default.
• W2051284343 hasConceptScore W2051284343C141071460 @default.
• W2051284343 hasConceptScore W2051284343C2776301958 @default.
• W2051284343 hasConceptScore W2051284343C2776413415 @default.
• W2051284343 hasConceptScore W2051284343C2776710957 @default.
• W2051284343 hasConceptScore W2051284343C2777091921 @default.
• W2051284343 hasConceptScore W2051284343C2778080469 @default.
• W2051284343 hasConceptScore W2051284343C2778261982 @default.
• W2051284343 hasConceptScore W2051284343C2778382381 @default.
• W2051284343 hasConceptScore W2051284343C2778661090 @default.
• W2051284343 hasConceptScore W2051284343C2778810321 @default.
• W2051284343 hasConceptScore W2051284343C2778961111 @default.
• W2051284343 hasConceptScore W2051284343C2779161974 @default.
• W2051284343 hasConceptScore W2051284343C2780434524 @default.
• W2051284343 hasConceptScore W2051284343C42219234 @default.
• W2051284343 hasConceptScore W2051284343C66112548 @default.
• W2051284343 hasConceptScore W2051284343C71924100 @default.
• W2051284343 hasConceptScore W2051284343C89560881 @default.
• W2051284343 hasIssue "2" @default.
• W2051284343 hasLocation W20512843431 @default.
• W2051284343 hasLocation W20512843432 @default.
• W2051284343 hasLocation W20512843433 @default.
• W2051284343 hasLocation W20512843434 @default.
• W2051284343 hasOpenAccess W2051284343 @default.
• W2051284343 hasPrimaryLocation W20512843431 @default.
• W2051284343 hasRelatedWork W1486815316 @default.
• W2051284343 hasRelatedWork W2041195426 @default.
• W2051284343 hasRelatedWork W2042662278 @default.
• W2051284343 hasRelatedWork W2051284343 @default.
• W2051284343 hasRelatedWork W2109065531 @default.
• W2051284343 hasRelatedWork W2138508804 @default.
• W2051284343 hasRelatedWork W2326969872 @default.
• W2051284343 hasRelatedWork W2913776432 @default.
• W2051284343 hasRelatedWork W2978248639 @default.
• W2051284343 hasRelatedWork W2990629389 @default.

• next